Histone deacetylase inhibitors

Abstract

Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas vapor. Such inhibitors can be used as therapeutics for numerous disease conditions, such as a variety of cancers, neural degenerative diseases, neurological diseases, senescence, and infectious diseases.

1 - 6 . (canceled) 
     
     
         7 . A method of inhibiting histone deacetylase (HDAC) in a subject in need thereof, comprising administering an effective amount of a volatile HDAC inhibitor compound to the subject via inhalation, wherein the volatile HDAC inhibitor compound is diacetyl, 2,3-butanediol, 2,3-pentanedione, or any combinations thereof. 
     
     
         8 . The method of  claim 7 , wherein the subject is a mammal. 
     
     
         9 . The method of  claim 7 , wherein the subject is a human. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is diacetyl. 
     
     
         12 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is nasally administered. 
     
     
         13 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is administered as a gas or vapor. 
     
     
         14 - 15 . (canceled) 
     
     
         16 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is 2,3-butanediol. 
     
     
         17 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is 2,3-pentanedione. 
     
     
         18 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is a combination of diacetyl, 2,3-butanediol, and 2,3-pentanedione. 
     
     
         19 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is a combination of diacetyl and 2,3-butanediol. 
     
     
         20 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is a combination of diacetyl and 2,3-pentanedione. 
     
     
         21 . The method of  claim 7 , wherein the volatile HDAC inhibitor compound is a combination of 2,3-butanediol and 2,3-pentanedione.